1887

Abstract

After passive transfer of measles virus (MV)-specific antibodies, vaccine-induced seroconversion and subsequent protection is inhibited in cotton rats (). In this system, an attenuated, recombinant vesicular stomatitis virus expressing the MV haemagglutinin (VSV-H) was found previously to induce neutralizing antibodies and protection against MV challenge after intranasal (i.n.) immunization. Here it is demonstrated that, after i.n. immunization, VSV-H is found in both lung and brain tissue in the absence of clinical signs. Intratracheal inoculation, which does not lead to infection of the brain, proved that immunization via the lung mucosa is sufficient to protect. To reduce or eliminate infection of the brain after i.n. inoculation, stepwise-attenuated VSV-H mutants with truncated cytoplasmic tails of the G protein were tested in cotton rats. A mutant with 9 aa in the G cytoplasmic tail was found at much lower levels in the brain and was protective in the absence or presence of MV-specific antibodies. A more attenuated mutant containing only 1 aa in its tail was not found in brain tissue after inoculation, but it still induced protective antibody to measles in the absence of MV-specific antibody. However, its ability to induce MV-neutralizing antibodies in the presence of passively transferred MV-specific antibodies and its protective capacity was abolished unless higher-dose immunizations were used. This study demonstrates that a lower degree of attenuation is required to be able to immunize in the presence of MV-specific antibodies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19050-0
2003-08-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/8/vir842145.html?itemId=/content/journal/jgv/10.1099/vir.0.19050-0&mimeType=html&fmt=ahah

References

  1. Chen R. T., Markowitz L. E., Albrecht P., Stewart J. A., Mofenson L. M., Preblud S. R., Orenstein W. A. 1990; Measles antibody: reevalution of protective titers. J Infect Dis 162:1036–1042
    [Google Scholar]
  2. Durbin A. P., Skiadopoulos M. H., McAuliffe J. M., Riggs J. M., Surman S. R., Collins P. L., Murphy B. R. 2000; Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 74:6821–6831
    [Google Scholar]
  3. Katz M. 1995; Clinical spectrum of measles. In Measles Virus pp  1–12 Edited by Billeter M, ter Meulen V. Berlin: Springer;
    [Google Scholar]
  4. Niewiesk S., Eisenhuth I., Fooks A., Clegg J. C. S., Schnorr J.-J., Schneider-Schaulies S., ter Meulen V. 1997; Measles virus-induced immune suppression in the cotton rat ( Sigmodon hispidus ) model depends on viral glycoproteins. J Virol 71:7214–7219
    [Google Scholar]
  5. Polack F. P., Lee S. H., Permar S. 8 other authors 2000; Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nature Med 6:776–781
    [Google Scholar]
  6. Reed L. J., Muench H. 1938; A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493–497
    [Google Scholar]
  7. Reiss C. S., Plakhov I. V., Komatsu T. 1998; Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci 855:751–761
    [Google Scholar]
  8. Roberts A. J., Kretzschmar E., Perkins A. S., Forman J., Price R., Buonocore L., Kawaoka Y., Rose J. K. 1998; Vaccination with a recombinant vesicular stomatits virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72:4704–4711
    [Google Scholar]
  9. Roberts A. J., Buonocore L., Price R., Forman J., Rose J. K. 1999; Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73:3723–3732
    [Google Scholar]
  10. Rose N. F., Marx P. A., Luckay A. 7 other authors 2001; An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539–549
    [Google Scholar]
  11. Schlereth B., Germann P.-G., ter Meulen V., Niewiesk S. 2000a; DNA vaccination with both the hemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J Gen Virol 81:1321–1325
    [Google Scholar]
  12. Schlereth B., Rose J. K., Buonocore L., ter Meulen V., Niewiesk S. 2000b; Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74:4652–4657
    [Google Scholar]
  13. Schnell M. J., Buonocore L., Kretzschmar E., Johnson E., Rose J. K. 1996; Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 93:11359–11365
    [Google Scholar]
  14. Schnell M. J., Buonocore L., Boritz E., Ghosh H. P., Chernish R., Rose J. K. 1998; Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J 17:1289–1296
    [Google Scholar]
  15. Stevenson P. G., Freeman S., Bangham C. R., Hawke S. 1997; Virus dissemination through the brain parenchyma without immunologic control. J Immunol 159:1876–1884
    [Google Scholar]
  16. Stittelaar K. J., Wyatt L. S., de Swart R. L. 7 other authors 2000; Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 74:4236–4243
    [Google Scholar]
  17. van Els C. A. C. M., Nanan R. 2002; T cell responses in acute measles. Viral Immunol 15:435–450
    [Google Scholar]
  18. Waynforth H. B., Flecknell P. A. 1992; Intratracheal administration. In Experimental and Surgical Technique in the Rat pp  27–31 San Diego: Academic Press;
    [Google Scholar]
  19. Weidinger G., Ohlmann M., Schlereth B., Sutter G., Niewiesk S. 2001; Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 19:2764–2768
    [Google Scholar]
  20. Wyde P. R., Ambrosi M. W., Voss T. G., Meyer H. L., Gilbert B. E. 1992; Measles virus replication in lungs of hispid cotton rats after intranasal inoculation. Proc Soc Exp Biol Med 201:80–87
    [Google Scholar]
  21. Wyde P. R., Moore-Poveda D. K., Daley N. J., Oshitani H. 1999; Replication of clinical measles virus strains in hispid cotton rats. Proc Soc Exp Biol Med 221:53–62
    [Google Scholar]
  22. Wyde P. R., Stittelaar K. J., Osterhaus A. D. M. E., Guzman E., Gilbert B. E. 2000; Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine 19:42–53
    [Google Scholar]
  23. Zhu Y., Rota P., Wyatt L., Tamin A., Rozenblatt S., Lerche N., Moss B., Bellini W., McChesney M. 2000; Evaluation of recombinant vaccinia virus: measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276:202–213
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19050-0
Loading
/content/journal/jgv/10.1099/vir.0.19050-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error